Dr. Ann Marie Egloff

About Dr. Ann Marie Egloff

Dr. Ann Marie Egloff was born in Owosso, Michigan, in a family emphasizing education and community involvement. Her mother, a sixth-grade science teacher, and her father, a public school educator and administrator, instilled in her a deep respect for learning and giving back. Throughout her years in school, she excelled academically, particularly in math and science, graduating from Swartz Creek High School with honors. In addition to her academic achievements, she participated in various extracurricular activities, including varsity basketball, track and field, and diving on the swim team. She also actively participated in student council, theater, and ballet with the Flint Institute of Music.

Dr. Egloff continued her academic journey at the University of Michigan, where she earned a Bachelor of Science degree in Cellular and Molecular Biology. This solid foundation in the sciences served as the stepping stone for her future career in biomedical research, with a focus on cancer and immunology.

Dr. Ann Marie Egloff’s professional research career began at Warner-Lambert Parke-Davis (now part of Pfizer) in Ann Arbor, Michigan, where she served as a Research Assistant. She received two employee recognition awards for her work on molecular cloning and the expression of therapeutic targets. Additionally, she contributed to evaluating small-molecule inhibitors used in cancer and metabolic disease departments. This hands-on laboratory experience deepened her research interest and motivated her to pursue further studies.

Dr. Egloff then pursued a PhD in Biochemistry, Cell, and Molecular Biology at the Johns Hopkins School of Medicine. Her doctoral research centered on immunology and protein biochemistry, specifically exploring immune cell signaling pathways that influence cellular responses. Her dissertation on this topic laid the groundwork for her future work in cancer immunotherapy and other areas of cancer research.

After completing her PhD, Dr. Ann Marie Egloff transitioned to a postdoctoral fellowship at the National Human Genome Research Institute (NHGRI). At NHGRI, she focused on cancer-causing gene mutations, earning an award for excellence in research. She also witnessed the completion of the human genome sequence. She participated in large-scale cancer genetic screening projects, which helped her realize the transformative potential of genomics in cancer treatment.

Building on this knowledge, Dr. Egloff pursued further training in translational cancer research. She joined the NIH/NCI-sponsored Cancer Education and Career Development Program at the University of Pittsburgh, where she earned a Master of Public Health in Epidemiology. In this role, she developed a deeper understanding of translating laboratory findings into clinical applications, focusing on creating personalized cancer therapies tailored to individual patients’ genetic profiles.

Dr. Ann Marie Egloff’s career flourished when she became a Research Associate Professor at the University of Pittsburgh School of Medicine. There, she focused on the genomics of head and neck squamous cell carcinoma (HNSCC) and cancer therapeutic vulnerabilities. As a principal investigator, she was pivotal in integrating genomic and proteomic data to guide personalized cancer treatments. Her work in these areas helped advance the field of personalized medicine and led to significant funding from major organizations, including the NIH.

Her research also contributed to developing clinical biospecimen resources, enabling groundbreaking discoveries through biomarker research and computational analysis. These innovations have had a lasting impact on cancer research and continue to guide future approaches to cancer treatment.

In 2015, Dr. Ann Marie Egloff moved to Boston University, where she held dual roles as a Research Associate Professor and Scientific Director in the Department of Otolaryngology: Head and Neck Surgery. She developed research infrastructure at Boston University, promoted mentorship, and encouraged interdepartmental collaboration. She also engaged with patient advisory boards to ensure that her research directly impacted patient care.

Dr. Egloff’s work continued to expand when she joined Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, where she serves as a lead investigator. She is also an Assistant Professor of Surgery at Harvard Medical School. Her ongoing research focuses on tumor immunology and precision medicine, exploring how personalized cancer immunotherapy can improve patient outcomes. By working closely with surgeons, physicians, and scientists, she continues translating her research into clinical therapies that directly benefit patients.